In summary, our results indicate that SOPs for ICM performance can be developed across three centers, that multi-center ICM can discriminate between CF patients with severe CFTR mutations and non-CF subjects, and that ICM (performed with common SOPs) can detect partial CFTR function in CF patients. Here, CFTR is linked to cystic fibrosis.